Rubella Diagnostic Testing Market driven by Rising number of rubella cases across the globe is expected to drive market expansion shortly at a CAGR of 5.60% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Rubella Diagnostic Testing Market” that contains information from 2019 to 2032. The Rubella Diagnostic Testing Market is estimated to register a CAGR of 5.60% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Rubella Diagnostic Testing Market— Abbott Laboratories Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Biokit SA, BioMérieux SA, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., ZEUS Scientific Inc.

Market Highlights

The global Rubella Diagnostic Testing Market is accounted to register a CAGR of 5.60% during the forecast period and is estimated to reach USD 2.16 billion by 2032

Government efforts to reduce the infection incidence, along with an increase in the number of rubella diagnostic tests and advancements in point-of-care diagnosis, are expected to drive market expansion during the projected period. Furthermore, government attempts to provide healthcare programs for free vaccinations as part of an end-to-end immunization program are projected to spur market expansion throughout the forecast period. Additionally, the introduction of new items by industry players is essential to the market.

 Segment Analysis

The global Rubella Diagnostic Testing Market has been segmented based on Testing Technique and Application.

Based on the Testing Technique, the market is segmented into Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), Fluorescent Immunoassay (FIA), and Other Testing Techniques. The Enzyme Immunoassay (EIA) segment was attributed to holding the largest market share in 2023. EIA reagents and devices are employed for antigen detection in tasks that connect to verifying epidemiological disease outbreaks through their widespread application for on-site diagnostics. In addition to these enzymes, bacterial cultures also possess high levels of certain enzymes, such as alkaline phosphatases and glucose oxidase. Rubella virus can linger in the circulatory system for several more years until it is swiped away by most of the antibodies that have been made by the immunity system. The most performed method when applied by commercial enzyme immunoassay (EIA) kits is IgM testing. The enzyme immunoassay (EIA) adds value here as a significant increase in antibody level is found from patients’ specimens matched in all cases that tested positive for acute rubella infection, and so it is also practically useful in identifying acute infections. The rising occurrence of infectious diseases like rubella is a catalyst leading to the increasing demand for immunoassay (EIA).

Based on the Application, the Rubella Diagnostic Testing Market has been segmented into Hospitals, Laboratories, and Other Applications. The hospitals segment was expected to hold the largest market share in 2023. It is mainly the growing population that has pulled up the number of quick testing techniques used in hospitals along with the application of various technologies that yield relatively quick results. On the other hand, the healthcare sub-sector has attained tremendous growth in the economy due to government funding and governmental policies. Noteworthy development of infectious diseases can spur the need for industry over the years to come.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Rubella Diagnostic Testing Market Research Report

Regional Analysis

The global Rubella Diagnostic Testing Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Rubella Diagnostic Testing Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Rubella Diagnostic Testing Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Rubella Diagnostic Testing Market comprises the Middle East, Africa, and Latin America.

The largest market share for the Rubella Diagnostic Testing Market was maintained by the North American regional sector. Governments' important strategies at the national level brought a reduction in Rubella incidents. In Canada, the measles incidence has escalated, with the number of new cases rising to 8 in week 14, 2024, while there were no new rubella cases reported. As of today, the number of measles cases is around 50 in Canada, with two confirmed patients with infections of congenital rubella syndrome. For example, in January 2022, the Government of Canada released that Canada was free from the measles and rubella diseases when the last week of 2021 (week 52) had already reached, and no cases of these diseases were recorded as active in Canada currently. As a result, the government's combined efforts to eliminate rubella with proper diagnostics are a primary driver for a strong market.

Moreover, the Europe market has been persistently growing over the forecast period. The introduction of vaccination measures in Europe led to a significant reduction in the frequency of Rubella outbreaks, but they have not entirely ceased to occur. WHO noted a huge increase in the number of measles cases around Europe, which exceeded 42,200 cases in 2023 against 941 cases of the virus in 2022 throughout the whole European Region. The recent reoccurrence of some infectious diseases of life, especially Rubella, is a matter of concern that is transmitting the tendency of Rubella. This has, thus, shifted the focus more towards more accurate and prompt diagnostic testing to prevent or suppress epidemics.

In the Asia Pacific region, due to the growing population and better healthcare facilities with convenient accessibility, significant growth of the market is expected. It may also bring about an increase in operational income associated with savings on cut healthcare fees, which in turn will drive market growth. According to the same fiscal year 2019 NHA report, there was a rise in the percentage of Government Health Expenditure (GHE) in the total GDP from 1.2% in the fiscal year 2014 (FY14) to 1.3% in the fiscal year 2019 (FY19). Besides this, the ratio of GHE to the Total Health Expenditure (THE) has also gradually risen over an elongated period, reaching 40.6 percent in FY19 and more than 28.6 percent in FY14. Asia Pacific region's big leaders are India, China, and Japan, which are at the top of the list since they have world-class and famous companies globally.

Furthermore, the rest of the world's Rubella Diagnostic Testing Market is divided into the Middle East, Africa, and Latin America. In 2011, as reported by both the Pan American Health Organization (PAHO) and the WHO, rubella infection-free status was declared for both the country of Colombia and the whole Latin America region, affirmed by both the PAHO and WHO. However, the epidemics of rubella tend to be resilient in emerging regions such as Africa and South East Asia. A tent total of 153 cases of rubella were reported in South Africa from week 1 to week 43, 2023. The people with the highest portion (121) of cases reported come from the Western Cape, with the Eastern Cape having the lowest number of cases (19). Vaccination regimens for rubella are not available in these regions. Thailand, Timor Leste, Macedonia, Tajikistan, and Syria topped the list of cases seen on Rubella as of 2013.

Key Findings of the Study

• The global Rubella Diagnostic Testing Market is expected to reach USD 2.16 billion by 2032, at a CAGR of 5.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because of the increasing government initiatives for the development of novel vaccines and therapies, as well as the comparatively lower cost of production.


• Based on Testing Technique, the Enzyme Immunoassay (EIA) segment was attributed to holding the largest market in 2023, with an approximate market share of 55–60%


• Abbott Laboratories Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Biokit SA, BioMérieux SA, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and ZEUS Scientific Inc. are the key market players.